Genespire is a preclinical stage biotechnology company, located in Milan, Italy, and co-founded by Fondazione Telethon, Ospedale San Raffaele, Pr. Luigi Naldini and Dr. Alessio Cantore.
At Genespire, we aim at improving the health of patients suffering from medical conditions that derive from inherited genetic diseases, through gene therapies, based on the exploitation of the in vivo “immune stealth” lentiviral vector platform and ex vivo improved targeted gene editing technologies, developed by Genespire’s scientific founders at SR-Tiget.
Genespire was established to leverage the potential of these technologies, with a main focus on inherited metabolic diseases and primary immunodeficiencies (PIDs). Our objective is to develop gene therapies, that are the most adapted to each targeted disease, and that will change the life of people who are not offered appropriate medical solutions today.